The therapy for intrahepatic cholangiocarcinoma (ICC) led to responses in about a quarter of patients and disease control in 85%. A new retrospective analysis of real-world intrahepatic ...
RFA and anti-PD-1 combination therapy suppresses abscopal HCC tumors and prevents recurrence in mice
Hepatocellular carcinoma (HCC), the most prevalent form of primary liver cancer, remains a leading cause of cancer-related mortality worldwide. Although radiofrequency ablation (RFA) is the first-line ...
A recent study found potential significance in PD-L1 analysis results for predicting immune treatment response in patients with advanced endometrial carcinoma. Additional biomarkers are needed to ...
SHANGHAI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...
NOTE. Extended FU data were received for 490 patients. Eighty-three patients had already died at the time of the 2-year analysis. Nine patients in the PD-1–treated arm and seven patients in the TT arm ...
We would like to comment on Schuler et al., on their well-designed randomized phase II NEOpredict-Lung study (NCT04205552) which was published in Nature Medicine. The main objective of this study was ...
Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART ...
SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results